Chronic Lymphocytic Leukemia

The application for lisocabtagene maraleucel in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has been accepted by the FDA, following positive results from the TRANSCEND CLL 004 study.

In the second article of a 2-part series, William G. Wierda, MD, PhD, looks at the efficacy and safety outcomes with the second generation BTK inhibitor zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Skye Montoya discussed noncovalent Bruton's tyrosine kinase inhibitors and mechanisms of resistance in chronic lymphocytic leukemia.

In the first article of a 2-part series, William G. Wierda, MD, PhD, discusses the role Bruton tyrosine kinase inhibitors play in the relapsed/refractory chronic lymphocytic leukemia setting.

Progression-free survival and overall survival data were maintained with fixed-duration venetoclax plus rituximab among patients with relapsed/refractory chronic lymphocytic leukemia

Findings of the phase 1b/2 EPCORE CLL-1 trial were presented during the International Workshop on CLL.

Findings from the phase 1/2 BRUIN trial of show a distinct genetic evolution in patients with B-cell malignancies. However, the baseline BTK mutations did not impede pirtobrutinib’s effectiveness.

In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.

Results from the BRUIN study focusing on patients with chronic lymphocytic leukemia/small lymphocytic lymphoma showed benefit in patients were pretreated with Bruton tyrosine kinase inhibitors.

Venetoclax has given new hope and better options to a notoriously hard-to-treat patient group.

Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.

Combination therapies utilizing ofatumumab could improve outcomes for patients with chronic lymphocytic leukemia, according to an analysis published in the Annals of Hematology.

Lisaftoclax is a novel, orally administered small-molecule BCL-2 selective inhibitor. A study of the agent in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma will commence in the second half of 2023.

In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.

Shared insight on ELEVATE-RR, which utilized acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Expert perspectives on the ALPINE trial of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Andrew Lipsky, MD, considers the role of BTK inhibitors as second-line therapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Cyrus M. Khan, discusses the current use of PI3K inhibitors to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and how recent ODAC decisions impacted their use.

Jennifer R. Brown, MD, PhD, highlights the results from the phase 3 ALPINE study evaluating the treatment with zanubrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Focused discussion on the first-line treatment armamentarium available to patients diagnosed with chronic lymphocytic leukemia.

Expert Andrew Lipsky, MD, reviews a patient case of relapsed/refractory chronic lymphocytic leukemia managed with BTK inhibition in the second-line setting.

Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

A watch-and-wait approach should remain the standard of care, even in the era of targeted therapies, in patients with early-stage chronic lymphocytic leukemia with inactive disease, according to data from the 2023 EHA Congress.

Patients aged 80 years or older and/or considered frail who received acalabrutinib for chronic lymphocytic leukemia experienced toxicities consistent with prior trials.

Results presented in a poster at the 2023 ASCO Annual Meeting demonstrated similar progression-free survival between acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia.